

Valencia, Iliana

From: Valencia, Iliana
Sent: Thursday, January 15, 2015 9:06 AM
To: 'akennedy@ebsi.com'
Subject: STN125562 Anthrax Immune Globulin Intravenous (Human): FDA Request

Our Reference: BL125562

Cangene Corporation
Attention: Allison Kennedy
January 15, 2015
Sent by Email

Dear Ms. Allison:

We are reviewing your July 25, 2014 biologics license application (BLA) for Anthrax Immune Globulin Intravenous (Human). We request that you make the following additional postmarketing commitment:

3. Cangene commits to (b) (4) [REDACTED] will be submitted to CBER as a CBE-0 by March 25, 2016.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

The action due date for this file is March 25, 2015.

Please send an acknowledgement for receipt of this request. And submit a response as an amendment to the file by January 26, 2015.

If you have any questions, please contact me.

Sincerely,

Iliana Valencia on behalf of Thomas Maruna.

Iliana Valencia, MS
Chief, Regulatory Project Management Staff
FDA/CBER/OBRR/IOD
240-402-8444
202-591-6054
iliana.valencia@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not

the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."